PPARA and metabolic dysfunction-associated steatotic liver disease: We hypothesized that VD may attenuate hepatic steatosis via the PPARα pathway and that these effects may be inhibited by MK886 in a NAFLD rat model and oleic acid (OA)-induced HepG2 cells.